P2X7 receptor antagonism preserves retinal ganglion cells in glaucomatous mice.
Glaucoma
P2X7 receptor
PERG
Retinal ganglion cells
Journal
Biochemical pharmacology
ISSN: 1873-2968
Titre abrégé: Biochem Pharmacol
Pays: England
ID NLM: 0101032
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
16
06
2020
revised:
29
07
2020
accepted:
11
08
2020
pubmed:
18
8
2020
medline:
1
1
2021
entrez:
18
8
2020
Statut:
ppublish
Résumé
To investigate the role of P2X7 receptor to preserve retinal ganglion cells (RGCs) structure and function in a genetic mouse model (DBA/2J mouse) of age-related glaucomatous neurodegeneration. Chronic treatment with P2X7 receptor antagonist eye drops was carried out in order to assess RGCs function and density by pattern electroretinogram (PERG) and RBPMS immunostaining, respectively. Further, microglia activation was assessed in flat-mounted retina by using Iba-1 immunostaining. Untreated glaucomatous eyes displayed significant microglia activation, alteration of PERG signal, and RGCs loss. In the P2X7 receptor antagonist-treated eyes, the PERG signal was significantly (p < 0.05) improved compared to controls, along with a significant (p < 0.05) reduction in terms of retinal microglial activation, and remarkable preservation of RGCs density. Altogether, these findings demonstrated that topical treatment with a P2X7 receptor antagonist has a neuroprotective effect on RGCs in glaucomatous mice, suggesting an appealing pharmacological approach to prevent retinal degenerative damage in optic neuropathy.
Identifiants
pubmed: 32798466
pii: S0006-2952(20)30435-4
doi: 10.1016/j.bcp.2020.114199
pii:
doi:
Substances chimiques
JNJ-47965567
0
Piperazines
0
Purinergic P2X Receptor Antagonists
0
Receptors, Purinergic P2X7
0
Niacinamide
25X51I8RD4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
114199Informations de copyright
Copyright © 2020. Published by Elsevier Inc.